American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
March 28, 2024
Earnings Call Speaker Segments
Stephanie Prince
executiveThanks, Betsy, and I appreciate all of you being with us today. Yesterday, once trading had ended, AMS put out its earnings press release for the fourth quarter of 2023. Should you require one, you can find it on the corporate site, ashs.com, listed among press releases beneath the Investors tab. Prior to handing things over to management, I want to offer a few comments regarding forward-looking statements. Be aware that a range of things we might say during this call relating to what we expect, plan, and foresee for the business going forward count as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Outcomes could differ substantially from what such forward-looking statements suggest, owing to numerous significant factors, among them those covered in the filings our company makes with the SEC. That takes in our quarterly report on Form 10-Q covering the 3-month stretches that closed on March 31, June 30, and September 30, 2023. It also takes in the annual report on Form 10-K covering the year that closed on December 31, 2022, plus the definitive proxy statement for the Annual Meeting of Shareholders, which took place on June 20, 2023. No duty is undertaken by the company to refresh any information provided on this conference call. Before handing the call to Ray, one reminder for participants: every questioner gets one question and one follow-up, no more. As ever, we're glad to handle further questions offline whenever you like. With that said, I'd like to pass the call now to Ray Stachowiak, Executive Chairman. Ray?
Ray Stachowiak
executiveI appreciate that, Stephanie, and hello everyone. We're glad you could be with us for the conference call on our 2023 fourth quarter earnings. I'll start with a few opening comments, then hand things over to our Chief Financial Officer, Bob Hiatt, who will walk through the financial details of the fourth quarter. Once the prepared portion is done, we'll take your questions. Before getting into our results, I want to recognize that we lost our founder and our longtime Chairman, CEO and friend, Dr. Earnst Bates. At the time of his death last week, Dr. Bates was 87. A board certified neurosurgeon, entrepreneur and philanthropist, he was widely respected and recognized as a pioneer and advocate for fair medical treatment in underserved communities. On a personal level, I had known Dr. Bates for many years. Back in 2009, he asked me to serve on the Board of American Shared, and he was a dear friend. All of us will surely miss him, his sound guidance and his wonderful humor. Now let me move on to our results. In 2023, AMS enjoyed a good year by virtually any standard. Things kept getting better as the months went on, and we moved forward on a number of key fronts. In particular, the sales group we assembled in the prior year has come together, and we closed out the year with the best sales pipeline we've seen in a long time. The reasons for this go beyond the team, whose members are widely recognized within our industry, and include our broader financial offerings and tighter coordination with our strategic OEMs. Combined, these elements have substantially widened the range of opportunities we can evaluate. Those opportunities span multiple types of advanced radiation equipment across different settings, plus an extension of our business model into developing proton beam and radiation oncology centers in the United States that we would majority-own. Under this expanded model, we would both own and run these centers. The team also deserves credit for reinforcing our core business by partnering with customers to boost how much they use their equipment and by helping secure 4 lease extensions; that means 4 out of our 10 domestic Gamma Knife customers have signed extensions during the past 15 months, with more still in the pipeline. In our view, these extended agreements demonstrate the strength of our partnership approach and our financial adaptability. International activity is picking up as well. During the fourth quarter, we finished upgrading the equipment in Ecuador to a new, state-of-the-art Gamma Knife ICON; it's the sole Gamma Knife in Ecuador for noninvasive radio surgery. Despite the time we lost while getting that system up and running, the quarter's volumes have still come in above where they were before. Patients will begin receiving treatment during the second quarter at our third facility outside the U.S., which is in Puebla, Mexico. A few weeks from now, when that site opens, the LINAC — the linear accelerator we put in, equipped for VMAT, IGRT and radiosurgery — is going to deliver the most sophisticated radiation therapy available to anyone in the area we serve. Money has continued to flow into 3 separate business opportunities I've mentioned before. We announced the first of these transactions in Q4: a deal to buy a 60% controlling interest in 3 radiation therapy cancer centers based in Rhode Island. The main takeaway here is that when this deal is finalized, those locations will be the first direct patient services or retail centers we operate within the U.S. We're looking forward to completing the transaction quickly and providing more information. Before that occurs, however, it's sufficient to note that we believe in this new venture. It's the initial one to emerge from our enlarged team and our refreshed pipeline, which demonstrates the direction we're pursuing as an organization. To repeat: upon closing this acquisition, we will hold and operate 60% ownership of our own radiation therapy centers in the United States. This aligns quite naturally as a progression of how our business model works. We closed out the year with the best quarter we've had, recording $5.7 million in total revenue for Q4, up 13% compared to the same period last year. Gross margin reached $2.8 million, a 24% rise, reflecting how we've kept a firm grip on direct costs while benefiting from positive operating leverage. As a share of revenue, gross margin was 49%, something we hadn't achieved since 2019. Q4 earnings per share were $0.06, even with $350,000 in Rhode Island costs and $362,000 in added reserves on impaired assets working against us; across all 12 months of 2023, revenue climbed 8% to $21.3 million. Gross margin totaled $9.3 million, up 11.5%. The gross margin percentage came to 44%. Even with $919,000 in Rhode Island expenses for the full year, plus another $940,000 set aside during the year for impaired assets and removal costs, we still delivered $0.10 per share. Those pressures should ease considerably as we move into 2024. Our balance sheet is in solid shape. Cash and equivalents stood at $13.8 million when the year closed, which works out to about $2.19 per share. We also finished the year with $4.5 million of availability under our $7 million line of credit, and that entire balance was paid off during the first quarter. We're putting in serious effort to turn these resources into new long-term revenue streams for the company. Turning to what's ahead, we anticipate accelerated growth outside the U.S., driven by extra treatment capacity in Ecuador plus the launch of our new facility in Puebla. Once the Rhode Island deal closes as expected, three more revenue streams will come into our business. Beyond that, several fresh business opportunities continue to move forward through our lengthy, complicated sales process. We're eager to share further specifics when the moment is right. With that, I'll hand things over to Bob for the financial rundown.
Bob Hiatt
executiveThank you, Ray, and good day to all of you. For the fourth quarter, revenue rose 13.1%, reaching $5.7 million, up from $5 million during the same quarter a year earlier; we also restructured our business segments so they better mirror where our revenue comes from. Leasing revenue — that's what we'll now call the medical equipment leasing segment — came to $4.8 million in Q4 of 2023, versus $4.3 million in last year's fourth quarter, which works out to a 12% gain. The Direct Patient Services segment, or Retail, brought in $913,000 for the quarter that ended December 31, 2023, compared with $764,000 during the matching period a year before, marking a 19.5% rise. In Florida, our Proton therapy system generated $3.1 million of fourth quarter revenue, up 39.9%, driven mostly by ongoing growth in average reimbursement along with greater traction. Proton therapy fractions totaled 1,275 in Q4, versus 981 in the fourth quarter of 2022 — a 30% jump, or 294 fractions, which sits inside the normal range of quarterly variation. Gamma Knife revenue overall fell 8.4%, landing at $2.6 million. That decline stems mainly from fewer procedures tied to 2 contracts that expired, plus downtime at 2 sites where upgraded equipment was being installed. Gamma Knife procedures came to 277 in the fourth quarter, down from 329 in the same quarter last year — a drop of 15.8%, or 52 procedures — reflecting those 2 expired contracts and the upgrade-related downtime I just mentioned. Gross margin for Q4 2023 climbed 24.1% to $2.8 million, against a gross margin of $2.3 million in the fourth quarter of 2022. As a percentage, gross margin hit a record 49.4%, versus 45.1% in the comparable quarter — the best sequential figure since 2019. Selling and administrative costs grew 23.9%, hitting $1.8 million in the fourth quarter of 2023, up from $1.4 million a year earlier. That figure includes roughly $350,000 we put toward chasing new business opportunities, which Ray discussed, along with elevated sales and marketing spending. Net interest expense came in at $175,000 for the 2023 period, compared with $192,000 in last year's comparable period. That drop reflects a higher interest rate on our variable rate debt, offset by more interest income from our growing cash balance. Operating income for Q4 2023 was $407,000, versus operating income of $590,000 in the fourth quarter of 2022 — a reflection of the bigger selling and administrative expenses, plus a $362,000 increase in reserves for impaired assets and removal costs during the current period. Income tax expense for the fourth quarter of 2023 was $338,000, slightly above the $333,000 recorded in the same period a year earlier; that was mainly because of higher taxable income, partially offset by permanent tax differences booked last year. For the fourth quarter of 2023, net income attributable to American Shared Hospital Services came in at $415,000, which works out to $0.06 per diluted share. That compares with net income of $246,000, or $0.04 per diluted share, in the fourth quarter of 2022. On a fully diluted basis, weighted average common shares outstanding stood at 6,552,000 for the fourth quarter of 2023 and 6,284,000 for the fourth quarter of 2022. Adjusted EBITDA, which is a non-GAAP financial measure, reached $2.7 million in the fourth quarter of 2023, versus $2.2 million in the fourth quarter of 2022. As of December 31, 2023, cash equivalents and restricted cash totaled $13.8 million, compared with $12.5 million as of December 31, 2022. Shareholders' equity, excluding noncontrolling interest to subsidiaries, was $22.6 million, or $3.59 per outstanding share, at year-end, versus $21.6 million, or $3.50 per outstanding share, at December 31, 2022. That wraps up the formal portion of our presentation. We appreciate you joining us today, and we look forward to bringing you updates on our progress in the quarters ahead. Leslie, we'd like to hand the call back to you and open it up for questions.
Tony Kamin
analystAbsolutely. So, I suppose, to begin with, I'd simply want to add my voice to what you said regarding Dr. Bates. He truly was a remarkable individual, and his passing is a significant loss. My initial question is this, Ray: I observed that in last year's full-year results, the Proton beam business came in at, I believe, $10.1 million in revenue, while the Gamma Knife was only slightly above that. So with just 1 proton beam, you're essentially reporting revenues roughly on par with the entire Gamma Knife operations. That's why I was pleased to hear you mention during your introduction that the company is exploring the possibility of seeking out proton beams it could fully own, in order to really get that segment of the business moving. Could you elaborate a bit further on that? And what do you view as the potential opportunity there? And anything — any additional detail about the proton beam side would be terrific.
Ray Stachowiak
executiveCertainly. That's an excellent point, Tony, and thank you for being with us once more today. I appreciate it. But indeed, we are quite deliberately going after proton beam opportunities, though not necessarily through a leasing structure like the revenue sharing arrangement we presently have in place with Orlando Health. Rather, we'd own and run our own proton beam centers ourselves, and we would extend an invitation for participation under that model to the local health care systems, ensuring a solid partnership among all parties in whichever region we choose to enter. However, we want to hold majority ownership of that own-and-operate approach. We've diversified in numerous respects over this past year or two; and here is yet another form of diversification. As for the Rhode Island acquisition, we are owning and operating our very own radiation therapy centers. We've already been doing this at our international sites, though not within the domestic market. And there are simply so many varied opportunities, because the way we've pivoted our business model unlocks an entire broader universe of possibilities for us to chase. And owning, operating, and maintaining majority control ownership of a proton beam radiation therapy center is part of our — is part of our business model; we're actively pursuing those opportunities. Tony.
Tony Kamin
analystYeah, I believe that would be excellent. And to build on that, regarding Rhode Island and GenesisCare — I'm aware their portfolio is quite large and broad. Might there be additional chances similar to the one you're currently working on in Rhode Island that could emerge from that GenesisCare circumstance?
Ray Stachowiak
executiveOutside of these Rhode Island opportunities with GenesisCare, we haven't gone after anything else. In Rhode Island, we've built up solid local management along with a strong understanding of what's possible there. And right now, I'd describe us as, shall we say, pausing for a beat.
Michael Cooper
analystGood afternoon, and I share the feelings expressed regarding Dr. Bates. It's sad to witness this loss. My question concerns Rhode Island. Could you explain what I understand to be the business model there, based on what I gathered from your recent news release and some other materials I read? So from what I can see, you have 3 clinics already operating with cutting-edge equipment, which I presume runs about $5 million for each site, roughly that kind of figure; and roughly 70 customers per day are coming in for procedures, as I understand it, and if I'm reading this right, one procedure brings in around $6,000, though I could be wrong on that; still, I believe that's the typical procedure charge you're currently receiving; so am I using the correct sort of figures for something like daily revenue, perhaps $400,000 in daily revenue across these 3 operations? And did you acquire roughly $15 million in equipment for $2.8 million?
Ray Stachowiak
executiveTony — Michael, rather, thank you for asking. I'm not quite prepared to reveal too much detail about this opportunity. We remain in the midst of closing the transaction, which we do anticipate will happen, I'd say, within the next 30 days. I can, I'd say, fix a few of your assumptions. We think the $6,000 for each procedure could be a suitable amount for each patient. And bear in mind, those patients may receive anywhere from 10 to 30 treatments for radiation therapy of cancer. So the 70 patients — 70 per day is closer to a treatment figure. Are you tracking with me?
Michael Cooper
analystYeah. Yeah.
Ray Stachowiak
executiveAll right. All right, so let me give you my thoughts. What I mean is, I'm certain our investors — their enthusiasm is somewhat tied to this. There are some broad things I can say, which is that we anticipate the revenue coming out of these 3 centers will land somewhere around $9 million to $10 million on an annual basis. That's a big jump compared with the $21 million per year that we have right now; and remember, we won't experience the complete impact of it during 2024, since we'll likely only have 8.5 months of revenue in 2024 out of that $9 million to $10 million. There's one more thing I can mention, which is that we anticipate our net income will be positive. I can anticipate a contribution to EBITDA stemming from this acquisition; but beyond that, I'm not able to say much more. What I can tell you is that 2 of the 3 centers have genuinely strong equipment, while 1/3 is less attractive. So that $5 million figure may not be a right assumption on your end either, Michael. All right. And that's likely the furthest I can go before crossing <<inaudible>>
Michael Cooper
analystThat's quite useful. Now, to build on that, might you shed some light on what kind of revenue Puebla, Mexico could bring, and also on the bump we'll get in Ecuador thanks to the equipment upgrade?
Ray Stachowiak
executiveThere's only so much I can say about specific cases. What I can share is that for Puebla, my expectation is no less than $1 million in additional revenue from that new revenue stream during the initial 12-month span, and again, we won't enjoy the benefit of a complete year in 2024 — it will kick in for all of 2025. Our plan is to treat our first patient in May of 2024. As for Ecuador, I believe that account will deliver some gains, though I'm not able to go into much detail on a single location. Does that answer your question?
Ray Stachowiak
executiveAbsolutely. One thing I want to highlight is that the Rhode Island acquisition boosts our revenue going forward pretty much right away. Once the deal closes, revenue recognition begins on day one following completion. That's a key difference — take what happened with Puebla, where we hold and run an 85% ownership stake, an arrangement we settled on in late 2022. Revenue from that hasn't started flowing yet and won't until the second quarter of 2024. That really illustrates just how lengthy the sales and implementation cycles can be for us sometimes. Expanding through acquisitions, on the other hand, delivers an instant lift to both revenue and profitability starting day 1. That's among the reasons I feel so strongly positive about this chance and eager to move forward on that path. So, with all that said, I want to express my thanks to everybody who was with us today. In my view, AMS has definitely reached a turning point. The future has us energized. And I hope you'll all keep watching. Our next conversation will be on the first quarter call in mid-May. Please reach out to us — get in touch directly if anything comes up before then. Take care and stay well. Thanks for spending your time with us today. Goodbye.
Operator
operatorThat brings us to the end of this call. We appreciate your joining us for today's presentation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.